{"id":"aspart-insulin-or-lipro-insulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aspart insulin is a recombinant human insulin analog with a single amino acid substitution (aspartic acid at position B28) that allows faster absorption and onset of action compared to regular human insulin. It binds to the insulin receptor on muscle, fat, and liver cells to facilitate glucose transport into cells and promote anabolic metabolism, effectively lowering blood glucose levels in diabetic patients.","oneSentence":"Aspart insulin is a rapid-acting insulin analog that binds to insulin receptors to promote glucose uptake and utilization in peripheral tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:41.705Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03226210","phase":"PHASE4","title":"Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2015-02-01","conditions":"Diabetes Mellitus, Type 2","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1684,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"aspart insulin or lipro insulin","genericName":"aspart insulin or lipro insulin","companyName":"Nanjing First Hospital, Nanjing Medical University","companyId":"nanjing-first-hospital-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aspart insulin is a rapid-acting insulin analog that binds to insulin receptors to promote glucose uptake and utilization in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}